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Complement regulatory proteins in glomerular diseases. Com-
plement activation plays a critical role in the pathogenesis of many
forms of glomerulonephritis. Complement activation leads to
tissue injury through various mechanisms including the generation
of chemotactic factors and activation of the resident glomerular
cells following C5b-9 insertion. Recent advances have disclosed
the mechanisms of regulation of complement activation by dis-
covery of a number of complement regulatory proteins. Decay
accelerating factor (DAF), membrane cofactor protein (MCP),
and complement receptor type 1 (CR1) act by inactivating C3/C5
convertase. They belong to the gene superfamily known as the
regulators of complement activation (RCA), and share a common
structural motif called a short consensus repeat (SCR). In con-
trast, CD59 works by inhibiting formation of C5b-9. The glomer-
ulus is particularly well endowed with these membrane-bound
complement regulatory proteins. DAF, MCP, and CD59 are
ubiquitously expressed by all three resident glomerular cells, while
CR1 is localized exclusively in podocytes. Expression of comple-
ment regulatory proteins can be changed by many factors includ-
ing complement attack itself, and their expression levels are
affected in various glomerular disorders. Studies utilizing cultured
glomerular cells and animal models of glomerular diseases suggest
important protective roles of complement regulatory proteins
against immune-mediated renal injury. Recent progress in molec-
ular biological techniques has made new therapeutic strategy
feasible. Systemic administration of soluble recombinant comple-
ment regulatory proteins and local overexpression of complement
regulatory proteins are promising therapeutic approaches.
Most forms of glomerulonephritis are associated with
immune deposits in glomeruli [1, 2]. In animals, the injuries
induced by the formation of immune complexes involving
glomerular or non-glomerular antigens are largely comple-
ment-dependent and can be greatly ameliorated, or pre-
vented entirely, by maneuvers that inhibit complement
activation [2, 3].
Complement activation, which usually works as a host
defense mechanism, causes renal damage and disease in
either of two circumstances: (i) when an antibody response
is made inappropriately to an autoantigen leading to for-
mation of immune complexes in kidney tissues or entrap-
ment of circulating immune complexes in glomeruli; and
(ii) when activation of the complement cascade is not
regulated appropriately. Glomeruli display antigenic
epitopes that can serve as targets for autoantibodies, and
studies utilizing the Heymann nephritis model of membra-
nous nephropathy in rats showed that complement activa-
tion induced by in situ immune complex formation on the
glomerular epithelial cell (GEC) membrane resulted in
complement-dependent proteinuria [1, 4]. In contrast to
membranous nephropathy, circulating immune complex
deposition is thought to play an important role in the
pathogenesis of lupus nephritis [5]. An example of inap-
propriate regulation of the complement cascade can be
human membranoproliferative glomerulonephritis
(MPGN) type I, in which the autoantibody termed C3
nephritic factor (C3 Nef) binds to and stabilizes C3 con-
vertase. C3 depletion caused by C3 Nef may impair pro-
cessing and clearances of immune complexes in the circu-
lation and cause MPGN type I, although C3 Nef may be
just an epiphenomenon in some cases because C3 Nef that
did not induce C3 splitting was also reported [6].
The balance between acceleration and inhibition of
complement activation is critical for the host regarding
whether the complement activation leads to host defense or
to tissue injury of host organs. Recent advances in the
complement researches have disclosed the mechanisms of
regulation of complement activation by an epoch-making
discovery of a number of complement regulatory proteins
present on the host cell membranes. This article provides
an overview of these advances as well as future perspectives
concerning the new therapeutic strategies for glomerular
injury.
COMPLEMENT ACTIVATION AND REGULATION
In animals and humans, the complement system, which
comprises more than 30 individual components, represents
one of the most powerful defenses against invading patho-
gens (Fig. 1).
The classical pathway is activated by the binding of C1q
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to antibody/antigen complexes, while the alternative path-
way can be initiated when spontaneously activated comple-
ment components bind to the surface of a pathogen. Once
complement activation is initiated by either pathway, the
C3 convertases (C4b2a and C3bBb) are generated that
cleave the intact C3 molecule into C3a and C3b fragments.
The newly generated C3b molecule forms another C3
convertase by the reaction of factor B and factor D. Thus,
the complement activation is accelerated at C3 level by this
amplification loop. Active C3b forms the C5 convertase and
initiates the formation of the membrane attack complex
(MAC) C5b-9, which is common to all these pathways.
Another pathway is the recently discovered lectin activation
pathway [7], which is initiated by the binding of mannose-
binding lectin (MBL) to carbohydrates on the surface of
microorganisms. The lectin pathway, like the classical path-
way, involves the generation of a C3-converting complex,
C4b2a, and contributes to efficient antimicrobial immunity
and protection, not only during the physiological window of
vulnerability in early childhood following the decay of
maternal antibody, but also in the early phase of every
primary contact with a sugar-rich pathogen.
While the complement system works as an effective host
defense, inappropriate complement activation leads to
tissue injury through various mechanisms [8, 9]. Glomeru-
lar injury mediated by complement was once thought to
occur primarily as a consequence of the generation of
chemotactic factors such as C3a and C5a that attracted
inflammatory cells as effectors. However, subsequent stud-
ies have shown that the nephritogenic effect of complement
activation may result from formation and insertion of MAC
in the resident glomerular cells [1, 4]. Although non-
nucleated cells may be lysed by C5b-9, nucleated cells are
usually resistant to lysis and may become activated by
insertion of sublytic quantities of C5b-9 [reviewed in 10].
The consequences of this process are multiple and include
cell proliferation [11], generation of inflammatory media-
tors such as oxidants, proteases, growth factors and prosta-
noids, and increased production of extracellular matrix.
Although the role of MAC is best established in experi-
mental membranous nephropathy where the primary target
is GEC, more recent studies have implicated the patho-
genic roles of MAC in the glomerular mesangial and
endothelial cell as well [12–14]. In addition, it is recognized
that complement activation causes glomerular injury not
only by recruitment of inflammatory cells and induction of
inflammatory mediators, but also by other mechanisms
including decreasing renal plasma flow as demonstrated by
Stahl’s group [15] and direct stimulation of glomerular cell
proliferation as shown in Shankland et al’s studies [11].
To prevent undesirable complement activation, rigorous
regulatory mechanisms are exhibited by host cells [reviewed
in 3, 16–18]. Control of complement activation is focused at
two stages in the pathway, the formation of the C3/C5
convertase and the assembly of the membrane attack
complex (C5b-9) (Table 1). While there are fluid-phase and
membrane-bound complement control proteins acting at
both of these stages, the membrane-bound inhibitors play a
vital role in limiting damage at the cell surface. The
glomerulus is particularly well endowed with complement
regulatory proteins expressed by all three resident glomer-
ular cells. Here I will focus primarily on the membrane
bound complement regulatory proteins.
FLUID PHASE COMPLEMENT REGULATORY
PROTEINS
Many investigators have shown that clusterin and S-
protein are detected in immune complexes formed in
Fig. 1. A schematic view of complement
activation and its regulation.
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glomerulonephritis [19–28]. These soluble complement
regulatory proteins may inactivate at least part of locally
activated C5b-9 in glomeruli (Table 1). Experimental ap-
proaches to elucidate the in vivo role for fluid phase
complement regulatory proteins in kidney disease have
only been attempted with clusterin. Perfusion of isolated
kidneys with anti-Fx1A antibody resulted in enhanced
glomerular MAC formation and increased proteinuria
when clusterin-depleted plasma was utilized by Saunders et
al [29].
Jansen, Hogasen, and their colleagues showed that factor
H deficiency causes hereditary MPGN type II in pigs [30,
31], which can be reversed by full-substitution therapy with
factor H concentrate [32]. While factor H deficiency is rare
in humans, it was repeatedly found in association with
various forms of glomerular diseases including MPGN [33,
34]. Furthermore, it was recently shown that mutations in
the factor H gene are associated with familial hemolytic
uremic syndrome [35].
MEMBRANE BOUND COMPLEMENT REGULATORY
PROTEINS
The first group of these complement regulatory proteins
acts by inactivating C3/C5 convertase via either of two
different mechanisms. DAF displaces C2a from C4b and
Bb from C3b. In contrast, MCP binds to membrane-
associated C3b and C4b and catalyzes their degradation by
factor I, serine protease in plasma. CR1 has both decay
accelerating activity and cofactor activity for factor I. Many
cells express more than one of these molecules, which may
work synergistically with different mechanisms of action.
DAF, CR1, and MCP belong to the gene superfamily
known as the regulators of complement activation (RCA),
located on the q32 band of chromosome 1. The encoded
genes in this genomic region of approximately 900 kb are
ordered C4BP, DAF, CR2, CR1, MCP-like, CR1-like, and
MCP in a 59 to 39 orientation, while the factor H gene lies
at a distance of more than 500 kb away from this region.
MCP-like and CR1-like are genomic elements that repre-
sent partial duplications of their respective genes, while it is
not known whether they are true genes that yield protein
products or pseudo-genes. The members of RCA have a
strikingly similar motif structure. This motif, called SCR or
a complement control protein (CCP) repeat, is a tightly
packed structure of approximately 60 amino acids held
together by two internal disulfide bridges formed by four
invariant cysteine residues.
Activation of the complement cascade is also regulated
at its final step, formation of MAC, by another membrane
bound complement regulatory protein, CD59.
In the human glomerulus, all four membrane-bound
complement regulatory proteins (MCP, DAF, CR1, and
CD59) are present (Table 2). The structures of these
proteins are shown in Figure 2, and more detail about each
of these complement regulatory proteins is provided below.
I will also mention a rodent protein, Crry, which has been
intensively studied in rodent models of renal disease.
Decay accelerating factor
Decay accelerating factor (DAF, CD55) acts by inhibit-
ing formation and accelerating decay of the C3/C5 conver-
tase, thereby limiting activation and deposition of C3.
Cloning of DAF cDNA has revealed a structure with four
contiguous SCRs [36, 37]. DAF is anchored to the plasma
membrane by a carboxy-terminal GPI linkage, while the
other two C3/C5 convertase inhibitors, CR1 and MCP, are
classical transmembrane proteins.
DAF is expressed on a wide variety of circulating cells
and tissues, and has been demonstrated in human glomer-
uli by immunoprecipitation [38]. DAF isolated from cul-
tured mesangial cells by Shibata, Cosio and Birmingham
demonstrated a molecular mass of 83 kD [39], while
immunoprecipitation of protein derived from human glo-
meruli showed a single band at 67 kD [38]. These results
Table 1. Complement regulatory proteins in humans
Initiation step
C1 inhibitor (C1-INH) Inactivates C1r and C1s; a serpin
Amplification loop
MCP Cofactor for factor I-mediated cleavage of
C3b and C4b
DAF Membrane-bound; Destabilizes C3/C5
convertases
CR1 Membrane-bound; Shows decay
accelerating activity as well as cofactor
activity
C4 binding protein
(C4BP)
Binds to C4b; Shows decay accelerating
activity as well as cofactor activity
Factor H Binds C3b; Shows decay accelerating
activity as well as cofactor activity
Factor I Degrades C3b and C4b aided by cofactors
C5b-9 formation
CD59 Blocks the final step of C5b-9 formation
on host cells
S-protein (vitronectin) Binds to C5b-7 and inhibits generation of
membrane attack complex
Clusterin (SP-40,40) Binds to C5b-7 and inhibits generation of
membrane attack complex
MCP, DAF, CR1 and CD59 are membrane-bound, while all others are
in the fluid-phase. Abbreviations are in the Appendix.
Table 2. Distribution of complement regulatory proteins in the kidney
DAF MCP CR1 CD59
Glomerular
endothelium
6 or 2 1 2 1
Mesangial cells 6 or 2 1 2 1
Glomerular
epithelial cells
6 or 2 1 1 1
Proximal tubules 1 or 2 1 2 1 or 2
Distal tubules 1 or 2 1 2 1
Collecting ducts 1 or 2 1 2 1
The word “or” means that there is a discrepancy among various reports.
Abbreviations are in the Appendix.
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clearly demonstrated DAF expression in glomerular cells.
Although DAF was barely detectable in glomerular cells
immunohistochemically [40–44], technical difficulty in de-
tecting DAF by immunohistochemistry could explain the
discrepancy.
The functional importance of DAF on glomerular cells
has been demonstrated by neutralizing it with antibody and
showing that GEC became more susceptible to comple-
ment mediated cytotoxicity [38]. DAF contained in mesan-
gial cell extracts was also shown to be functionally active
and inhibited complement mediated hemolysis [39].
Membrane cofactor protein
Membrane cofactor protein (MCP, CD46) is also a
regulatory protein that is widely distributed on almost every
cell and tissue, with the curious exception of the erythro-
cyte. MCP serves as a cofactor for the factor I-mediated
degradation of C3b and C4b. Cloning of MCP cDNA,
performed by Lublin from Atkinson’s group, revealed that
it was a typical type 1 membrane glycoprotein with four
SCRs [45].
MCP is clearly seen in all three different types of human
Fig. 2. Schematic structures of human
membrane-bound complement regulatory
proteins. Decay accelerating factor (DAF) and
membrane cofactor protein (MCP) are
composed of four short consensus repeat (SCR)
structures. This is followed by an STP segment,
which is rich in serines, threonines, and prolines
and is extensively O-glycosylated. In MCP this
region is followed by a segment of unidentified
function, a transmembrane domain, and one of
two alternatively spliced cytoplasmic tails. DAF
is tethered to the cell membrane by a glycosyl-
phosphatidylinositol (GPI)-anchor that is added
post-translationally. Complement receptor type
1 (CR1) has an interesting structural
arrangement in which contiguous blocks of
every seven SCR form a larger highly
homologous repeating array called a long
homologous repeat (LHR). Thus, the
extracellular domain of the common form of
CR1 is composed of four LHR with two
additional SCR (a total of 30 SCR).
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glomerular cells by immunohistochemical analysis [40, 42,
46]. As seen in most tissues, glomerular MCP showed
molecular weight heterogeneity consisting of two major
components with 45 to 65 kD on SDS-PAGE [40], a
distinguishing structural characteristic of MCP. The two
distinct forms result from alternative splicing in the region
of O-glycosylation.
Nakanishi et al showed that cofactor activity in the
extracts of cultured GEC and mesangial cells assessed with
fluorescence-labeled substrate C3 and purified factor I was
completely blocked by anti-MCP antibody [40].
Complement receptor type 1
Complement receptor type 1 (CR1, CD35) is a polymor-
phic membrane protein of 190 to 280 kD that is expressed
on the surface of various circulating cells and, interestingly,
podocytes. CR1 has four allotypes: A (or F), B (or S), C,
and D. Fearon’s group showed that the most common A
allotype has a molecular mass of 250 kD when analyzed by
reducing SDS-PAGE, and has 30 SCRs [47, 48].
CR1 mediates phagocytosis of particles opsonized with
C3b and acts as cofactor for the breakdown of C3b and C4b
by the fluid-phase regulator Factor I. Decay accelerating
activity has also been attributed to CR1. Aside from these
functions, CR1 on erythrocytes has a unique role in the
transport and clearance of immune complexes from the
circulation.
In glomeruli, CR1 is localized exclusively on podocytes
[40, 49–51]. CR1 was also detected only in cultured GEC
[40, 52, 53] in contrast to the other membrane-bound
complement regulatory proteins that were present in any
cultured glomerular cells [39, 40, 54, 55]. Quigg et al
demonstrated that cultured rat glomerular epithelial cells
express 4.5 kb CR1 mRNA which encodes a 200 kD protein
[52, 53]. However, the precise functional role of CR1 in
podocytes remains to be determined.
Complement regulatory protein, CD59
CD59 is also known as membrane inhibitor of reactive
lysis (MIRL), homologous restriction factor-20 (HRF-20),
or protectin. CD59 is an 18,000 ; 20,000 molecular weight
GPI-anchored glycoprotein, and binds to the a-subunit of
C8 and the C9b domain of C9, preventing formation of a
lytic lesion by limiting incorporation of C9 into C5b-9
complexes. The mature protein consists of 77 amino acids
with no significant similarities to any of the other comple-
ment regulatory proteins [56–59].
CD59 is also ubiquitously expressed on all three glomer-
ular cells [40, 42, 44, 60–63]. Cultured glomerular epithe-
lial, endothelial, and mesangial cells have been shown to
have increased susceptibility to complement-mediated lysis
in the presence of neutralizing antibody to CD59 in vitro
[54, 55, 60, 64]. An important role of CD59 in vivo was
demonstrated utilizing two different models of comple-
ment-dependent glomerulonephritis. Matsuo et al perfused
anti-CD59 antibody into kidneys of rats with experimental
mesangial proliferative glomerulonephritis induced with a
lectin as a planted antigen [65]. Neutralization of CD59
resulted in more severe glomerular damage in their model.
Nangaku et al also performed selective renal artery perfu-
sion of anti-CD59 in a thrombotic microangiopathy model
in rats induced with antibody to endothelial cells [66]. Rats
perfused with anti-CD59 showed more glomerular C5b-9
formation and more severe endothelial damage associated
with more platelet and fibrin deposition in glomeruli and a
decrease in renal function [67]. These studies suggest that
CD59 has an important protective role in glomeruli subject
to complement attack.
Rodent protein, Crry
In humans, DAF and MCP work at a C3/C5 convertase
step by different mechanisms. In addition to DAF and
MCP, rodents have a single protein known as Crry that
serves the complement regulatory role of both these pro-
teins. Cloning of rat cDNA for Crry revealed a structure
composed of a signal peptide, six or seven SCRs, a trans-
membrane, and an intracytoplasmic domain [68, 69].
In rats Crry is expressed on the membrane of glomerular
mesangial, endothelial, and epithelial cells [54, 55, 70]. Crry
has been demonstrated immunohistochemically in glomer-
ular capillary walls and mesangial cells in normal rats [70]
and mice [71].
Quigg et al showed the functional importance of Crry in
cultured glomerular cells utilized neutralizing antibody to
Crry [54, 55]. Matsuo and his colleagues have elucidated
protective roles of Crry in vivo through animal studies.
Their elegant studies suggested that normal vascular per-
meability is maintained by Crry through controlling com-
plement activation on endothelial cells [72, 73]. Renal
artery perfusion of Fab2 fragments of anti-Crry in normal
rats resulted in marked renal tubulointerstitial damages,
implying that Crry protects normal kidneys from spontane-
ous complement activation [74]. Suppression of glomerular
Crry by antibody in the anti-thymocyte serum (ATS) model
of glomerulonephritis in rats also resulted in more severe
mesangiolysis and microaneurysm formation [75].
EXPRESSION OF COMPLEMENT REGULATORY
PROTEINS
Human studies
Expression of complement regulatory proteins can be
changed by complement attack itself and other factors such
as cytokines.
Cosio, Shibata and their colleagues demonstrated that
early complement components increased DAF mRNA [76],
while they also showed that C5b-9 formation caused an
increase of DAF at the protein levels in cultured mesangial
cells [39]. An increase of MCP and CD59 protein levels was
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also induced by complement activation in cultured mesan-
gial cells [76, 77]. The up-regulation of CD59 was con-
trolled by at least two steps of the complement pathway, C5
and C8.
Treatment of cultured GEC with various cytokines did
not change the expression levels of MCP, DAF, and CR1,
while CD59 was up-regulated by IL-1b and TGF-b [78].
REGULATION OF COMPLEMENT REGULATORY
PROTEINS
In vivo studies
Some reports have analyzed the expression levels of
complement regulatory proteins in human diseased kidneys
in vivo.
MCP was up-regulated in some diseased kidneys such as
membranoproliferative glomerulonephritis, IgA nephropa-
thy, and lupus [46]. The enhanced staining for MCP
colocalized with C3b/C3c, an indicator of on-going comple-
ment activation, and it was speculated that up-regulation of
MCP was stimulated by nascently generated complement
fragments. Up-regulation of MCP in IgA nephropathy was
also reported recently by Ootaka et al with a mild correla-
tion with proteinuria [79].
DAF, which was barely detected in normal kidneys
except in the juxtaglomerular apparatus, was up-regulated
in the glomerular mesangium and renal interstitium of
diseased kidneys, and correlated with C1q and C3 deposi-
tion [41].
CR1 expression in podocytes was lost in some glomerular
diseases such as rapidly progressive glomerulonephritis,
membranous nephropathy, diabetic glomerulosclerosis,
and lupus nephritis [51, 80–88]. This may be explained by
the loss of podocytes or a metabolic abnormality of the
podocytes.
Expression of CD59 in glomerular capillary walls was
increased in diffuse lupus nephritis, which might be a
protective response against the complement mediated in-
jury in this disease [62]. Although a slight increase of CD59
expression was also reported in minimal change disease and
IgA nephropathy in the same study, the differences in these
disorders from normal kidneys did not reach statistical
significance. In contrast, Lehto from Meri’s group showed
that the expression of CD59 in glomeruli was decreased in
patients with membranous nephropathy, accompanied by
an increase of urinary CD59 excretion [89]. The mechanism
of increased urinary CD59 is unclear and may reflect
shedding of CD59 from GEC induced by complement
attack.
Genetically engineered animals overexpressing or lack-
ing genes of complement regulatory proteins (transgenic
animals or knock-out mice) will be great tools to investigate
their roles in glomerulonephritis in vivo. Recent studies
utilizing transgenic mice that overexpress soluble Crry
under the control of the inducible promoter demonstrated
a significant reduction in albuminuria in the nephrotoxic
serum nephritis model (R.J. Quigg, personal communica-
tion).
POTENTIAL THERAPEUTIC APPLICATIONS OF
COMPLEMENT REGULATORY PROTEINS IN
GLOMERULAR DISEASE
Many pharmacological agents have been reported to
inhibit complement activation. However, none of these
agents are suitable in the clinical context. Heparin, perhaps
the most studied of these, is a rather weak inhibitor. Cobra
venom factor is widely used in experimental animals, but
toxic side effects including fatal anaphylaxis preclude its use
in humans. Many other complement blockers function as
nonspecific protease inhibitors and, therefore, could affect
other important serum proteases.
The lack of a good pharmaceutical inhibitor of comple-
ment led researchers to seek alternatives. One possible
approach is to utilize a blocking antibody against comple-
ment component that inhibits the complement cascade [90,
91]. Monoclonal antibody against C5 is currently in phase I
trials for the prevention of inflammation during cardiopul-
monary bypass. However, recent progress in molecular
biological techniques has made completely new approaches
feasible. These new techniques include systemic adminis-
tration of soluble recombinant protein (Table 3) and local
overexpression of complement regulatory proteins at the
cellular level.
The first report that applied reagents produced by mo-
lecular techniques to treat immunological glomerular dis-
eases through complement modulation in vivo was pub-
lished by Couser and colleagues in 1995 [92]. In this
insightful study, they utilized a soluble recombinant CR1
(sCR1) lacking the transmembrane and cytoplasmic do-
mains. Intraperitoneal administration of 60 mg/kg per day
of sCR1 significantly reduced mesangiolysis, platelet and
macrophage infiltration, and urine protein excretion in the
ATS model of mesangial proliferative glomerulonephritis.
sCR1 treatment also resulted in significant reduction of
glomerular injury, associated with a decrease in proteinuria
Table 3. Solubilized forms of complement regulatory proteins as a
therapeutic application
Produced by In vivo studies
Soluble MCP [98, 99] 293-EBNA-
transformed
Xenograft rejection,
Arthus reaction
Soluble DAF [100] CHO Arthus reaction
CAB-2 [106] CHO-K1 Arthus reaction,
Forsmann shock
Soluble CR1 [92–97] CHO ATS model, PHN model,
Con A model, PAN
model, allograft
rejection, HD
Soluble Crry [102] Pichia pastoris Not performed
Crry-Ig chimera [103] Transgenic
mouse
Nephrotoxic serum
nephritis
Soluble CD59 [101] Sf9 Not performed
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in both the passive Heymann nephritis model of membra-
nous nephropathy and the concanavalin A/anti-concanava-
lin A model of glomerulonephritis mediated by subendo-
thelial formation of immune complexes. Therapeutic
efficacy of sCR1 has also been demonstrated in several
other forms of tissue injury, including tubulointerstitial
injury due to leakage of complement components in mas-
sive proteinuria [93, 94], rejection of kidney allografts [95],
and complement activation during hemodialysis [96, 97].
sCR1 is now undergoing human clinical testing, and is
being evaluated in a phase IIa trial for adult respiratory
distress syndrome and a phase I/II trial of reperfusion
injury following lung transplantation.
Recombinant soluble MCP has been shown to be effec-
tive by Christiansen and colleagues in hyperacute graft
rejection in a xenograft model [98] and in the reverse
passive Arthus reaction model [99]. There is no report of
administration of recombinant soluble MCP in kidney
disease to my knowledge.
A novel secreted form of DAF has been generated by a
deletion of the signal for the GPI anchor by Moran et al
[100]. While this form of DAF reduced the severity of a
reversed Arthus reaction, it was a less potent inhibitor of
complement mediated hemolysis than GPI-linked DAF.
Truncated soluble CD59 has been prepared using recom-
binant baculovirus-infected insect cells by Sugita and his
colleagues. Recombinant soluble CD59 inhibited reactive
hemolysis, although its activity was much less than that of
purified erythrocyte CD59 [101]. Soluble CD59 has not
been tested in vivo.
Recently Quigg’s group succeeded in producing a func-
tional soluble recombinant Crry utilizing a yeast expression
system [102]. The recombinant protein was highly active
against both the classical and alternative pathways of
complement. Quigg and Holers also developed a Crry-Ig
chimera, which showed a significant protective effect in the
nephrotoxic serum nephritis model of mice [103].
Although sCR1 was effective in glomerulonephritis mod-
els in rats, it is not ideal. It is a very large molecule (200 kD)
that must be given systemically and has a relatively short
half-life in the circulation. Soluble recombinant forms of
DAF and MCP can share many of these problems, al-
though this remains to be tested. Current research is thus
focused on the development of more active forms of the
inhibitors utilizing data obtained by more detailed analysis
on the function-structure relationship of various comple-
ment regulatory proteins. Removal of the single N-linked
glycosylation site of CD59 resulted in an enhancement of
complement inhibitory activity [104]. The complement reg-
ulating activity of CR1 could be increased by changing a
few amino acids within SCRs [105]. A soluble chimeric
form of DAF and MCP with eight SCRs in total was shown
to inactivate both classical and alternative C3/C5 converta-
ses via two different mechanisms: factor I-mediated prote-
olysis of C3b and enhancement of convertase decay. This
protein, named CAB-2, was more competent as a comple-
ment inhibitor than the soluble forms of either DAF or
MCP [106]. These studies will guide the engineering of new
inhibitors containing just the active site with minimal
framework residues to provide a small, stable, and active
inhibitor.
Another fascinating and more challenging way to mod-
ulate complement activation at a molecular level is to
perform in vivo gene transfer of complement regulatory
proteins. As a first step in exploring this technique, in
studies in Dr. Couser’s laboratory, we transfected cultured
glomerular cells with expression vectors containing comple-
ment regulatory protein cDNA [107, 108]. Our stably
transfected mesangial cell lines overexpressing CD59-
FLAG or Crry-c-myc showed remarkable resistance to both
lytic complement attack and the sublytical effects of C5b-9,
which supported the feasibility of this kind of approach. To
date, no successful studies of in vivo gene transfer of
complement regulatory proteins have been reported.
We can develop another potential novel strategy for
therapeutic intervention utilizing a characteristic feature of
GPI-linked molecules. GPI-linked proteins can detach
from the host membrane and reintegrate into another [109,
110]. GPI-mediated transfer of complement regulatory
proteins such as DAF and CD59 may provide another
possible way to treat complement mediated diseases and
spare us any risks of perturbing gene expression in vivo,
which always is a concern associated with gene therapy.
Complement regulatory proteins can be utilized in a
completely different way. In hyperacute xenograft rejec-
tion, fixation of complement is known to be crucial. To
abrogate the hyperacute rejection, transgenic animals ex-
pressing human complement regulatory proteins have been
developed [111]. Since the demand for organ transplants is
greater than the supply of human donor organs, xenotrans-
plantation may become an alternative to allograft trans-
plantation. Those who suffer from chronic renal failure due
to glomerulonephritis (and other diseases) may benefit
from transgenic allogenic organs overexpressing human
complement regulatory proteins [112].
SUMMARY AND CONCLUSION
Uncontrolled complement activation either in extent or
location is detrimental, and host cells have developed a
complex system of proteins that regulate potentially harm-
ful complement activation and prevent tissue injury in vivo,
the so-called complement regulatory proteins. Three mem-
brane-bound complement regulatory proteins, DAF, MCP,
and CR1, control activation of the complement cascade at
the C3/C5 convertase level, while CD59 regulates C5b-9
formation. In the glomerulus, CR1 is localized exclusively
in podocytes, while DAF, MCP, and CD59 are ubiquitously
expressed in glomerular epithelial, endothelial, and mesan-
gial cells. Expression levels of these proteins are altered by
complement attack and in various diseases. Recent studies
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utilizing cultured glomerular cells and animal models of
glomerulonephritis suggest that complement regulatory
proteins play an important protective role against immune-
mediated glomerular injury. Recent technological advances
have made manipulation of complement regulatory pro-
teins a feasible and promising therapeutic approach for the
future.
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APPENDIX
Abbreviations used in this article are: ATS, anti-thymocyte serum; CCP,
complement control protein; C3 Nef, C3 nephritic factor; CR1, comple-
ment receptor type 1; Crry, rodent complement regulatory protein; DAF,
decay accelerating factor; GEC, glomerular epithelial cell; GPI, glycosyl-
phosphatidylinositol; MAC, membrane attack complex; MBL, mannose-
binding lectin; MCP, membrane cofactor protein; MIRL, membrane
inhibitor of reactive lysis; MPGN, membranoproliferative glomerulone-
phritis; RCA, regulators of complement activation; SCR, short consensus
repeat; sCR1, soluble recombinant complement regulatory protein type 1.
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